Login Register Cart 0
Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Assessing Myocardial Involvement in Systemic Lupus Erythematosus Patients without Cardiovascular Symptoms by Technetium-99m-sestamibi Myocardial Perfusion Imaging: A Correlation Study on NT-proBNP

Author(s): Kejing Shao, Fenghong Yuan, Fei Chen, Jianfeng Wang, Xiaoliang Shao, Feifei Zhang, Bao Zhu and Yuetao Wang*

Volume 19, Issue 10, 2023

Published on: 21 December, 2022

Article ID: e231122211148 Pages: 9

DOI: 10.2174/1573405619666221123103546

Price: $65

Abstract

Background: In patients with systemic lupus erythematosus (SLE), myocardial involvement is the third leading course of death after lupus nephropathy (LN) and infections. Previous autopsy studies have demonstrated a high incidence of cardiovascular abnormalities in the myocardium. However, the patients with typical symptoms are far much fewer than expected from post-mortem examinations.

Objectives: The current study aimed to evaluate the technetium-99m-sestamibi (99mTc-MIBI) gated myocardial perfusion imaging (GMPI) characteristics of lupus patients without cardiovascular symptoms, and the relationships between GMPI characteristics and biochemical markers of myocardial injury, and to explore the role of GMPI in assessing myocardial involvement.

Methods: Thirty patients were studied with rest myocardial perfusion imaging, and summed rest score (SRS), summed motion score (SMS), and summed thickening score (STS) were calculated automatically. Biomarkers, including N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and creatine-kinase-MB (CK-MB), were detected simultaneously. GMPI parameters, LV functions and biomarkers were compared between two NT-proBNP groups. The relationships between these parameters were studied by correlation analysis.

Results: SMS, STS, and glomerular filtration rate (eGFR) were the main influencing factors of NTproBNP level (p = 0.001, <0.001, 0.042, respectively). Thirteen patients with an evaluated concentration of NT-proBNP had the lower left ventricular ejection fraction (LVEF), peak filling rate (PFR), eGFR and higher levels of CK-MB (in all comparisons, p < 0.05), and SRS was the only influencing factor of NT-proBNP (p = 0.007). Within thirteen patients with SRS≥2, there was a significant correlation between SRS and NT-proBNP (p < 0.001).

Conclusion: 99mTc-MIBI GMPI could evaluate the left ventricular function and prompt the cardiomyocyte function at the cellular level. SMS and STS were the main influencers for plasma NT-proBNP, and SRS was the independent factor for elevated NT-proBNP. This radionuclide imaging method could provide additional diagnostic information on myocardial involvement in patients with SLE.

Graphical Abstract

[1]
Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019; 393(10188): 2344-58.
[http://dx.doi.org/10.1016/S0140-6736(19)30546-X] [PMID: 31180031]
[2]
Hermansen ML, Lindhardsen J, Torp-Pedersen C, Faurschou M, Jacobsen S. The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: A Danish nationwide population-based cohort study. Rheumatology (Oxford) 2017; 56(5): kew475.
[http://dx.doi.org/10.1093/rheumatology/kew475] [PMID: 28053276]
[3]
Aviña-Zubieta JA, To F, Vostretsova K, De Vera M, Sayre EC, Esdaile JM. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: A general population-based study. Arthritis Care Res (Hoboken) 2017; 69(6): 849-56.
[http://dx.doi.org/10.1002/acr.23018] [PMID: 28129475]
[4]
Vavlukis M, Pop-Gjorcevab D, Poposka L, Sandevska E, Kedev S. Myocardial infarction in systemic lupus erythematosus – the sex-specific risk profile. Curr Pharm Des 2021; 27(29): 3221-8.
[http://dx.doi.org/10.2174/1381612826666201210110809] [PMID: 33302858]
[5]
Haque S, Gordon C, Isenberg D, et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: The lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol 2010; 37(2): 322-9.
[http://dx.doi.org/10.3899/jrheum.090306] [PMID: 19955047]
[6]
Mueller C, McDonald K, de Boer RA, et al. Heart failure association of the European society of cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019; 21(6): 715-31.
[http://dx.doi.org/10.1002/ejhf.1494] [PMID: 31222929]
[7]
Neilan TG, Rothenberg ML, Amiri-Kordestani L, et al. Myocarditis associated with immune checkpoint inhibitors: An expert consensus on data gaps and a call to action. Oncologist 2018; 23(8): 874-8.
[http://dx.doi.org/10.1634/theoncologist.2018-0157] [PMID: 29802220]
[8]
Schillaci O, Laganà B, Danieli R, et al. Technetium-99m sestamibi single-photon emission tomography detects subclinical myocardial perfusion abnormalities in patients with systemic lupus erythematosus. Eur J Nucl Med Mol Imaging 1999; 26(7): 713-7.
[http://dx.doi.org/10.1007/s002590050442] [PMID: 10398819]
[9]
Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40(9): 1725.
[http://dx.doi.org/10.1002/art.1780400928] [PMID: 9324032]
[10]
Hecht H, Blaha MJ, Berman DS, et al. Clinical indications for coronary artery calcium scoring in asymptomatic patients: Expert consensus statement from the society of cardiovascular computed tomography. J Cardiovasc Comput Tomogr 2017; 11(2): 157-68.
[http://dx.doi.org/10.1016/j.jcct.2017.02.010] [PMID: 28283309]
[11]
Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29(2): 288-91.
[PMID: 11838846]
[12]
Jung J, Kim YH, Kim N, Yang DH. Patient-specific 17-segment myocardial modeling on a bull’s-eye map. J Appl Clin Med Phys 2016; 17(5): 453-65.
[http://dx.doi.org/10.1120/jacmp.v17i5.6237] [PMID: 27685120]
[13]
Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the cardiac imaging committee of the council on clinical cardiology of the American heart association. Circulation 2002; 105(4): 539-42.
[http://dx.doi.org/10.1161/hc0402.102975] [PMID: 11815441]
[14]
Germano G, Kavanagh P, Slomka P, Vankriekinge S, Pollard G, Berman D. Quantitation in gated perfusion SPECT imaging: The cedars-sinai approach. J Nucl Cardiol 2007; 14(4): 433-54.
[http://dx.doi.org/10.1016/j.nuclcard.2007.06.008] [PMID: 17679052]
[15]
Sharir T, Germano G, Waechter PB, et al. A new algorithm for the quantitation of myocardial perfusion SPECT. II: Validation and diagnostic yield. J Nucl Med 2000; 41(4): 720-7.
[PMID: 10768575]
[16]
Wijetunga M, Rockson S. Myocarditis in systemic lupus erythematosus. Am J Med 2002; 113(5): 419-23.
[http://dx.doi.org/10.1016/S0002-9343(02)01223-8] [PMID: 12401537]
[17]
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of America. Circulation 2017; 136(6): e137-61.
[http://dx.doi.org/10.1161/CIR.0000000000000509] [PMID: 28455343]
[18]
Sabatine MS, Morrow DA, de Lemos JA, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 2004; 44(10): 1988-95.
[http://dx.doi.org/10.1016/j.jacc.2004.07.057] [PMID: 15542281]
[19]
Szathmáry V, Osvald R. An interactive computer model of propagated activation with analytically defined geometry of ventricles. Comput Biomed Res 1994; 27(1): 27-38.
[http://dx.doi.org/10.1006/cbmr.1994.1004] [PMID: 8004940]
[20]
Sharir T, Berman DS, Waechter PB, et al. Quantitative analysis of regional motion and thickening by gated myocardial perfusion SPECT: Normal heterogeneity and criteria for abnormality. J Nucl Med 2001; 42(11): 1630-8.
[PMID: 11696631]
[21]
Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996; 28(4): 964-71.
[http://dx.doi.org/10.1016/S0735-1097(96)00268-9] [PMID: 8837575]
[22]
Ogawa T, de Bold AJ. Uncoordinated regulation of atrial natriuretic factor and brain natriuretic peptide in lipopolysaccharide-treated rats. Biomarkers 2012; 17(2): 140-9.
[http://dx.doi.org/10.3109/1354750X.2011.643487] [PMID: 22224641]
[23]
Yucel T, Memiş D, Karamanlioglu B, Süt N, Yuksel M. The prognostic value of atrial and brain natriuretic peptides, troponin I and C-reactive protein in patients with sepsis. Exp Clin Cardiol 2008; 13(4): 183-8.
[PMID: 19343164]
[24]
Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther 2011; 13(4): 228.
[http://dx.doi.org/10.1186/ar3349] [PMID: 21745419]
[25]
Howe HS, Leung BPL. Anti-cytokine autoantibodies in systemic lupus erythematosus. Cells 2019; 9(1): 72.
[http://dx.doi.org/10.3390/cells9010072] [PMID: 31892200]
[26]
Moonen M, Lancellotti P. Update on myocarditis. Rev Med Liege 2018; 73(5-6): 269-76.
[PMID: 29926565]
[27]
Zheng Y, Ye L, Cen X, Lin J, Fu J, Wang L. Low NT-proBNP levels: An early sign for the diagnosis of ischemic heart failure. Int J Cardiol 2017; 228: 666-71.
[http://dx.doi.org/10.1016/j.ijcard.2016.11.139] [PMID: 27883979]
[28]
Wang L, Cong H, Zhang J, et al. Prognostic significance of preprocedural N-terminal Pro-B-type natriuretic peptide assessment in diabetic patients with multivessel coronary disease undergoing revascularization. Front Cardiovasc Med 2021; 8: 721260.
[http://dx.doi.org/10.3389/fcvm.2021.721260] [PMID: 34692781]
[29]
Zelt JGE, Liu PP, Erthal F, et al. N-terminal Pro B-type natriuretic peptide and high-sensitivity cardiac troponin T levels are related to the extent of hibernating myocardium in patients with ischemic heart failure. Can J Cardiol 2017; 33(11): 1478-88.
[http://dx.doi.org/10.1016/j.cjca.2017.06.012] [PMID: 28966019]
[30]
Sella EMC, Sato EI, Leite WA, Oliveira Filho JA, Barbieri A. Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Ann Rheum Dis 2003; 62(11): 1066-70.
[http://dx.doi.org/10.1136/ard.62.11.1066] [PMID: 14583569]
[31]
Sandevska E, Gjorcheva DP, Vavlukis M, et al. Myocardial perfusion abnormalities in young and premenopausal women with systemic lupus erythematosus, detected with 99MTC MIBI myocardial perfusion scintigraphy – prevalence and correlation with proatherogenic factors. Prilozi (Makedon Akad Nauk Umet Odd Med Nauki) 2018; 39(2-3): 79-92.
[http://dx.doi.org/10.2478/prilozi-2018-0045] [PMID: 30864359]
[32]
Ukena C, Kindermann M, Mahfoud F, et al. Diagnostic and prognostic validity of different biomarkers in patients with suspected myocarditis. Clin Res Cardiol 2014; 103(9): 743-51.
[http://dx.doi.org/10.1007/s00392-014-0709-z] [PMID: 24781421]
[33]
Piwnica-Worms D, Kronauge JF, Chiu ML. Enhancement by tetraphenylborate of technetium-99m-MIBI uptake kinetics and accumulation in cultured chick myocardial cells. J Nucl Med 1991; 32(10): 1992-9.
[PMID: 1919744]
[34]
Matsuo S, Nakajima K, Kinuya S. Evaluation of cardiac mitochondrial function by a nuclear imaging technique using technetium-99m-MIBI uptake kinetics. Asia Ocean J Nucl Med Biol 2013; 1(1): 39-43.
[PMID: 27408841]
[35]
Jia E, Geng H, Liu Q, et al. Cardiac manifestations of Han Chinese patients with systemic lupus erythematosus: A retrospective study. Iran J Med Sci 2019; 188(3): 801-6.
[http://dx.doi.org/10.1007/s11845-018-1934-7] [PMID: 30460452]
[36]
Liu B, Yu W, Wang J, et al. Incremental value of regional wall motion abnormalities for detecting obstructive coronary artery disease by rest-only electrocardiogram-gated single-photon emission computerized tomography myocardial perfusion imaging in suspected coronary artery disease patients. Nucl Med Commun 2021; 42(3): 276-83.
[http://dx.doi.org/10.1097/MNM.0000000000001335] [PMID: 33252509]
[37]
Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J 2013; 34(33): 2636-48.
[http://dx.doi.org/10.1093/eurheartj/eht210]
[38]
Mavrogeni S, Bratis K, Markussis V, et al. The diagnostic role of cardiac magnetic resonance imaging in detecting myocardial inflammation in systemic lupus erythematosus. Differentiation from viral myocarditis. Lupus 2013; 22(1): 34-43.
[http://dx.doi.org/10.1177/0961203312462265] [PMID: 23035042]
[39]
Zhang Y, Corona-Villalobos CP, Kiani AN, et al. Myocardial T2 mapping by cardiovascular magnetic resonance reveals subclinical myocardial inflammation in patients with systemic lupus erythematosus. Int J Cardiovasc Imaging 2015; 31(2): 389-97.
[http://dx.doi.org/10.1007/s10554-014-0560-3] [PMID: 25352245]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy